IRCT20160422027520N19 IRCT 2021-10-12 Tabriz University of Medical Sciences Intradermal injection of lymphocytes in recurrent pregnancy loss patients RPL Intradermal lymphocyte therapy in recurrent pregnancy loss patients with immunologic abnormalities 2021-10-22 anticipated 200 Complete https://irct.ir/trial/59154 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: At first, the sample size of 200 patients with RPL that met our inclusion criteria was considered as the total sample size. 'Random allocation rule' method was used for randomization, where numbers were randomly assigned to cards on a random order of one to 200. Even numbers were assigned to the treatment group and odd numbers to the placebo group. In this method, the balance will be reached at the end of the study in the number of people assigned to each group. Each card was placed in sealed and opaqued envelopes to hide the random assignment, Blinding description: The participants and the person who analyzed the results were blinded in this study. Participants were aware of the study before being randomized and informed consent was obtained from them. It should be noted that the person analyzing the results had no other role in this study. 1-2 Recurrent Pregnancy Loss(RPL). Intervention group: The group of 200 patients with recurrent miscarriage was randomly divided into two groups of 100, one group receiving lymphocyte therapy and the other group not receiving treatment. Is injected. According to the standard protocol, 2 × 107 of husband's lymphocytes are injected subcutaneously into patients with recurrent miscarriages. The number of injections is three times and at intervals of one month.. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more data